BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1409 related articles for article (PubMed ID: 28752853)

  • 1. Regulation of Hippo pathway transcription factor TEAD by p38 MAPK-induced cytoplasmic translocation.
    Lin KC; Moroishi T; Meng Z; Jeong HS; Plouffe SW; Sekido Y; Han J; Park HW; Guan KL
    Nat Cell Biol; 2017 Jul; 19(8):996-1002. PubMed ID: 28752853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear phosphoinositide signaling promotes YAP/TAZ-TEAD transcriptional activity in breast cancer.
    Jung O; Baek MJ; Wooldrik C; Johnson KR; Fisher KW; Lou J; Ricks TJ; Wen T; Best MD; Cryns VL; Anderson RA; Choi S
    EMBO J; 2024 May; 43(9):1740-1769. PubMed ID: 38565949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The receptor tyrosine kinase EphA2 promotes glutamine metabolism in tumors by activating the transcriptional coactivators YAP and TAZ.
    Edwards DN; Ngwa VM; Wang S; Shiuan E; Brantley-Sieders DM; Kim LC; Reynolds AB; Chen J
    Sci Signal; 2017 Dec; 10(508):. PubMed ID: 29208682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RAC-LATS1/2 signaling regulates YAP activity by switching between the YAP-binding partners TEAD4 and RUNX3.
    Jang JW; Kim MK; Lee YS; Lee JW; Kim DM; Song SH; Lee JY; Choi BY; Min B; Chi XZ; Bae SC
    Oncogene; 2017 Feb; 36(7):999-1011. PubMed ID: 27425596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review.
    Crawford JJ; Bronner SM; Zbieg JR
    Expert Opin Ther Pat; 2018 Dec; 28(12):867-873. PubMed ID: 30482112
    [No Abstract]   [Full Text] [Related]  

  • 6. Hippo Component TAZ Functions as a Co-repressor and Negatively Regulates ΔNp63 Transcription through TEA Domain (TEAD) Transcription Factor.
    Valencia-Sama I; Zhao Y; Lai D; Janse van Rensburg HJ; Hao Y; Yang X
    J Biol Chem; 2015 Jul; 290(27):16906-17. PubMed ID: 25995450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A YAP/TAZ-induced feedback mechanism regulates Hippo pathway homeostasis.
    Moroishi T; Park HW; Qin B; Chen Q; Meng Z; Plouffe SW; Taniguchi K; Yu FX; Karin M; Pan D; Guan KL
    Genes Dev; 2015 Jun; 29(12):1271-84. PubMed ID: 26109050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the acylation of TEAD4 on its interaction with co-activators YAP and TAZ.
    Mesrouze Y; Meyerhofer M; Bokhovchuk F; Fontana P; Zimmermann C; Martin T; Delaunay C; Izaac A; Kallen J; Schmelzle T; Erdmann D; Chène P
    Protein Sci; 2017 Dec; 26(12):2399-2409. PubMed ID: 28960584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcriptional co-repressor function of the hippo pathway transducers YAP and TAZ.
    Kim M; Kim T; Johnson RL; Lim DS
    Cell Rep; 2015 Apr; 11(2):270-82. PubMed ID: 25843714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reciprocal regulation of YAP/TAZ by the Hippo pathway and the Small GTPase pathway.
    Jang JW; Kim MK; Bae SC
    Small GTPases; 2020 Jul; 11(4):280-288. PubMed ID: 29457552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-hippo kinases: indispensable roles in YAP/TAZ signaling and implications in cancer therapy.
    Zhu J; Wu T; Lin Q
    Mol Biol Rep; 2023 May; 50(5):4565-4578. PubMed ID: 36877351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allosteric Modulation of the YAP/TAZ-TEAD Interaction by Palmitoylation and Small-Molecule Inhibitors.
    Mills KR; Misra J; Torabifard H
    J Phys Chem B; 2024 Apr; 128(16):3795-3806. PubMed ID: 38606592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1.
    Janse van Rensburg HJ; Azad T; Ling M; Hao Y; Snetsinger B; Khanal P; Minassian LM; Graham CH; Rauh MJ; Yang X
    Cancer Res; 2018 Mar; 78(6):1457-1470. PubMed ID: 29339539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cysteine S-Glutathionylation Promotes Stability and Activation of the Hippo Downstream Effector Transcriptional Co-activator with PDZ-binding Motif (TAZ).
    Gandhirajan RK; Jain M; Walla B; Johnsen M; Bartram MP; Huynh Anh M; Rinschen MM; Benzing T; Schermer B
    J Biol Chem; 2016 May; 291(22):11596-607. PubMed ID: 27048650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The PDZ-binding motif of Yes-associated protein is required for its co-activation of TEAD-mediated CTGF transcription and oncogenic cell transforming activity.
    Shimomura T; Miyamura N; Hata S; Miura R; Hirayama J; Nishina H
    Biochem Biophys Res Commun; 2014 Jan; 443(3):917-23. PubMed ID: 24380865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hippo-YAP/TAZ signalling coordinates adipose plasticity and energy balance by uncoupling leptin expression from fat mass.
    Choi S; Kang JG; Tran YTH; Jeong SH; Park KY; Shin H; Kim YH; Park M; Nahmgoong H; Seol T; Jeon H; Kim Y; Park S; Kim HJ; Kim MS; Li X; Bou Sleiman M; Lee E; Choi J; Eisenbarth D; Lee SH; Cho S; Moore DD; Auwerx J; Kim IY; Kim JB; Park JE; Lim DS; Suh JM
    Nat Metab; 2024 May; 6(5):847-860. PubMed ID: 38811804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway.
    Chen M; Wang M; Xu S; Guo X; Jiang J
    Oncotarget; 2015 Dec; 6(42):44466-79. PubMed ID: 26561204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel role for microRNA-129-5p in inhibiting ovarian cancer cell proliferation and survival via direct suppression of transcriptional co-activators YAP and TAZ.
    Tan G; Cao X; Dai Q; Zhang B; Huang J; Xiong S; Zhang Yy; Chen W; Yang J; Li H
    Oncotarget; 2015 Apr; 6(11):8676-86. PubMed ID: 25895125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Hippo pathway terminal effector TAZ/WWTR1 mediates oxaliplatin sensitivity in p53 proficient colon cancer cells.
    Slaninová V; Heron-Milhavet L; Robin M; Jeanson L; Aissanou A; Kantar D; Tosi D; Bréhélin L; Gongora C; Djiane A
    BMC Cancer; 2024 May; 24(1):587. PubMed ID: 38741073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TAZ/YAP fusion proteins: mechanistic insights and therapeutic opportunities.
    Garcia K; Gingras AC; Harvey KF; Tanas MR
    Trends Cancer; 2022 Dec; 8(12):1033-1045. PubMed ID: 36096997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 71.